Persistent Asset Partners Ltd Raises Stock Position in ANI Pharmaceuticals, Inc. $ANIP

Persistent Asset Partners Ltd grew its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 98.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 14,320 shares of the specialty pharmaceutical company’s stock after buying an additional 7,112 shares during the period. Persistent Asset Partners Ltd’s holdings in ANI Pharmaceuticals were worth $1,130,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in ANIP. Advisors Asset Management Inc. purchased a new position in shares of ANI Pharmaceuticals in the 1st quarter worth $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of ANI Pharmaceuticals by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock worth $736,000 after buying an additional 470 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of ANI Pharmaceuticals by 0.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock worth $3,235,000 after buying an additional 423 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of ANI Pharmaceuticals in the 1st quarter worth $2,706,000. Finally, Norges Bank purchased a new position in shares of ANI Pharmaceuticals in the 2nd quarter worth $625,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Trading Up 0.9%

NASDAQ:ANIP opened at $83.00 on Wednesday. ANI Pharmaceuticals, Inc. has a one year low of $62.60 and a one year high of $99.50. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. The firm has a market cap of $1.89 billion, a P/E ratio of 21.01 and a beta of 0.44. The firm has a 50-day simple moving average of $80.06 and a 200-day simple moving average of $79.40.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, beating the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The business had revenue of $237.46 million during the quarter, compared to analyst estimates of $207.63 million. During the same quarter in the previous year, the business posted $1.70 EPS. The company’s quarterly revenue was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 8.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, June 1st. Five research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, ANI Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $107.33.

Insider Activity

In related news, SVP Ori Gutwerg sold 2,772 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $79.50, for a total transaction of $220,374.00. Following the completion of the transaction, the senior vice president owned 78,696 shares in the company, valued at $6,256,332. The trade was a 3.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Patrick D. Walsh sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $80.63, for a total transaction of $806,300.00. Following the transaction, the director owned 38,432 shares of the company’s stock, valued at approximately $3,098,772.16. This trade represents a 20.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 79,016 shares of company stock worth $6,195,991 over the last 90 days. 8.10% of the stock is currently owned by insiders.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.